Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intramuscular, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | India | Malaysia | Philippines | Taiwan | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Monash University Malaysia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Skin Diseases, Infectious|Lung Diseases, Fungal|Gram-Negative Bacterial Infections|HIV Infections|Measles|Skin Cancer|Salmonella Infections, Animal|Tuberculosis, Oral|Influenza, Human|Tuberculosis, Cutaneous|Lung Cancer|Skin Diseases, Bacterial|Diphtheria|Malaria|Immune Complex Diseases|Inflammation|Skin Diseases, Genetic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500101828 |
ChiCTR2500101828 | N/A |
Not yet recruiting |
Non-Small-Cell Lung Cancer |
2028-04-30 |
|||
ACTRN12624001057572 |
ACTRN12624001057572 | N/A |
Not yet recruiting |
Unknown |
2025-06-30 |
2025-04-28 |
Treatments |
|
NCT04753892 |
21HH6540 | N/A |
Completed |
Healthy Volunteers |
2022-07-20 |
2022-07-28 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT01397604 |
BYI-0736 | P1 |
Completed |
Tuberculosis, Oral|Skin Cancer|Immune Complex Diseases|Lung Diseases, Fungal|Skin Diseases, Genetic|Malaria|Measles|Skin Diseases, Infectious|Lung Cancer|HIV Infections|Gram-Negative Bacterial Infections|Inflammation|Tuberculosis, Cutaneous|Influenza, Human|Diphtheria|Salmonella Infections, Animal|Skin Diseases, Bacterial |
2013-03-01 |
2023-12-08 |
Primary Endpoints|Treatments |